Biotechnology

Filter

Current filters:

None

Popular Filters

1976 to 2000 of 2365 results

Expanded Access Program for enzalutamide agreed with US FDA

30-05-2012

The US Food and Drug Administration agreed that Medivation (Nasdaq: MDVN) and Japanese drug major Astellas…

Astellas PharmaBiotechnologyenzalutamideMDV3100MedivationNorth AmericaOncologyPharmaceuticalRegulation

US legislation could block public access to drug safety information, claim consumer groups

30-05-2012

A provision in the Food and Drug Administration Reform Act that would block public access to potentially…

BiotechnologyNorth AmericaPharmaceuticalPoliticsRegulation

Genentech links up with Ensemble Thera for macrocyclic drug candidates discovery

30-05-2012

Swiss drug major Roche's (ROG: SIX) subsidiary Genentech has initiated a drug discovery collaboration…

BiotechnologyEnsemble TherapeuticsGenentechLicensingResearchRoche

Rainbow BioSci seeks to develop treatment for traumatic brain injury

29-05-2012

USA-based Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp (OTCBB: RBCC) revealed yesterday…

Amarantus BioSciencesBiotechnologyLicensingNeurologicalRainbow Biosciences

UK health and life sciences group agrees new clinical trials transparency principles

28-05-2012

The Ethical Standards in Health and Life Sciences Group (ESHLSG), a partnership including the Association…

BiotechnologyEuropePharmaceuticalRegulationResearch

EMA orphan drug committee makes 16 recommendations at May meeting

28-05-2012

The European Medicines Agency's Committee for Orphan Medicinal Products (COMP) adopted a total of 16…

Alexion PharmaceuticalsBiotechnologyeculizumabEuropePharmaceuticalRare diseasesRegulation

US Senate passing of FDA Safety and Innovation Act lauded by biotech and pharma industry

28-05-2012

The US Senate approved the Food and Drug Administration Safety and Innovation Act (FDASIA), which includes…

BiotechnologyFinancialLegalNorth AmericaPharmaceuticalPoliticsRegulation

EMA confirms Roche's MabThera made at Vacaville site poses no health risk

28-05-2012

Following a quality review of the genetically engineered monoclonal antibody MabThera, the European Medicines…

Anti-Arthritics/RheumaticsBiotechnologyMabTheraOncologyPharmaceuticalRegulationRoche

Positive results for Regeneron and Sanofi's SAR236553/REGN727

27-05-2012

USA-based Regeneron (Nasdaq: REGN) and French drug major Sanofi (Euronext: SAN) presented results of…

BiotechnologyCardio-vascularPharmaceuticalRegeneronResearchSanofi

Israel's Thrombotech and D-Pharm to merge

25-05-2012

intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical…

BiotechnologyD-PharmHadasit Bio-HoldingsMergers & AcquisitionsThrombotech

Australia's TGA launches consultation on better medicines labeling

24-05-2012

Australia's medicine's regulator, the Therapeutic Goods Administration, has this week released a consultation…

Asia-PacificBiotechnologyGenericsPharmaceuticalRegulation

Pharma companies "must be held fully accountable for defrauding US government," says Public Citizen

23-05-2012

Public Citizen strongly supports a measure proposed by US Senator Bernie Sanders (Independent, Vermont)…

BiotechnologyLegalMarkets & MarketingNorth AmericaPharmaceuticalPolitics

French biotechnology a sector in need of new growth solutions

23-05-2012

The biotechnology industry in France is a dynamic sector mainly made up of small structures, but companies…

BiotechnologyEuropeFinancialMergers & Acquisitions

Almost 2,300 clinical trials to be conducted in Central Europe in 2014

23-05-2012

The Central European (CE) region has, in recent years, been extensively affected by changes in global…

BiotechnologyEuropePharmaceuticalResearch

AusBiotech marks Clinical Trials Day with call for action

22-05-2012

Marking International Clinical Trials Day 2012 (May 20), Australian biotech industry trade group AusBiotech…

Asia-PacificBiotechnologyPoliticsResearch

Emerging discoveries offer opportunities for uncommon genetic disorders

22-05-2012

Groundbreaking therapies are on the horizon as scientists explore new treatment options for rare genetic…

BiotechnologyGeneticsMarkets & MarketingPharmaceuticalResearch

Milestone for Active Biotech in tasquinimod collaboration with Ipsen

22-05-2012

Sweden's Active Biotech (Nasdaq OMX Nordic: ACTI) has received a 10 million-euro ($127 million) milestone…

Active BiotechBiotechnologyFinancialIpsenOncologyPharmaceuticalResearchtasquinimod

New study shows Japan most expensive for investing in clinical trials, followed by Australia

21-05-2012

A new international report on the global competitiveness of 14 countries has ranked Japan competitive…

BiotechnologyGlobalPharmaceuticalResearch

World's first stem cell drug, Osiris' Prochymal, approved in Canada

21-05-2012

USA-based Osiris Therapeutics (Nasdaq: OSIR) has received market authorization from Health Canada to…

BiotechnologyImmunologicalsNorth AmericaOsiris TherapeuticsProchymalRegulation

72% complete response in Ph II leukemia study of Amgen's blinatumomab

21-05-2012

USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech firm, has announced updated results…

AmgenBiotechnologyblinatumomabMicrometOncologyResearch

New analysis of risk stratification for Biogen and Elan's Tysabri

20-05-2012

US biotech company Biogen Idec (Nasdaq: BIIB) and Ireland-based partner Elan (NYSE: ELN) said that a…

Biogen IdecBiotechnologyElanNeurologicalPharmaceuticalResearchTysabri

Foreign efforts to lure US biopharmaceutical companies

20-05-2012

Despite increasing budget pressures, countries around the world are making substantial investments in…

BiotechnologyFinancialGlobalNorth AmericaPharmaceuticalPoliticsResearch

1976 to 2000 of 2365 results

Parexel

Parexel

Back to top